Jump to main content
Jump to site search

Issue 5, 2019
Previous Article Next Article

Mechanism of thienopyridone and iminothienopyridinedione inhibition of protein phosphatases

Author affiliations

Abstract

Thienopyridone (TP) has been proposed as a selective inhibitor of phosphatases of regenerating liver (PRL or PTP4A). PRLs are dual specificity phosphatases that promote cancer progression and are attractive anticancer targets. TP and iminothienopyridinedione (ITP), a more potent derivative, were shown to be effective inhibitors but the mechanism of inhibition was not established. Here, we perform NMR experiments and in vitro phosphatase assays to show that TP and ITP inhibit protein phosphatases non-specifically through oxidation of the phosphatase catalytic cysteine. We demonstrate that TP and ITP are redox active compounds, inhibiting PRL-3 and multiple other PTPs through oxidation. They also catalyze the oxidation of thioredoxin-1 as well as small molecules, like TCEP, DTT, and glutathione. The reported selectivity of TP and ITP is likely due to the higher susceptibility of PRLs to oxidation. Thus, while TP and ITP effectively inhibit PRLs, their use for studying the cellular function of PRLs is problematic due to the likelihood of off-target effects.

Graphical abstract: Mechanism of thienopyridone and iminothienopyridinedione inhibition of protein phosphatases

Back to tab navigation

Supplementary files

Publication details

The article was received on 22 Mar 2019, accepted on 02 Apr 2019 and first published on 05 Apr 2019


Article type: Research Article
DOI: 10.1039/C9MD00175A
Med. Chem. Commun., 2019,10, 791-799

  •   Request permissions

    Mechanism of thienopyridone and iminothienopyridinedione inhibition of protein phosphatases

    Z. Zhang, G. Kozlov, Y. S. Chen and K. Gehring, Med. Chem. Commun., 2019, 10, 791
    DOI: 10.1039/C9MD00175A

Search articles by author

Spotlight

Advertisements